TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05660408

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pp65/tumor mRNA RNA-LP (DP2)
Description: This is a patient specific RNA-LP vaccine generated from the patient's tumor RNA.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pp65/tumor mRNA RNA-LP (DP2)
Description: This is a patient specific RNA-LP vaccine generated from the patient's tumor RNA.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pp65/tumor mRNA RNA-LP (DP2)
Description: This is a patient specific RNA-LP vaccine generated from the patient's tumor RNA.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pp65/tumor mRNA RNA-LP (DP2)
Description: This is a patient specific RNA-LP vaccine generated from the patient's tumor RNA.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pp65/tumor mRNA RNA-LP (DP2)
Description: This is a patient specific RNA-LP vaccine generated from the patient's tumor RNA.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Biopsy/Resection
Description: Eligible participants will be enrolled and undergo sterile collection of tumor material .

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Biopsy/Resection
Description: Eligible participants will be enrolled and undergo sterile collection of tumor material .

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Biopsy/Resection
Description: Eligible participants will be enrolled and undergo sterile collection of tumor material .

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Biopsy/Resection
Description: Eligible participants will be enrolled and undergo sterile collection of tumor material .

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Biopsy/Resection
Description: Eligible participants will be enrolled and undergo sterile collection of tumor material .
Study: NCT06280092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMSCs
Description: A single dose of 5x10\^6 AMSCs will be resuspended in 1ml of LRS and infused via intraparenchymal at the time of DBS surgery
Study: NCT06110988

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pan-vascular interventional robotic system
Description: Pan-vascular interventional robotic system assited PCI for delivery and manipulation of guidewires, catheters, and quick exchange balloon dilatation catheters/stents.
Study: NCT04859829

Intervention type: OTHER
Intervention: Current Intravenous Immunoglobulin (IVIG) treatment
Description: Questionnaires every two months for patients with a diagnosis of autoimmune dysmotility that are receiving Intravenous Immunoglobulin (IVIG) treatment.

Intervention type: OTHER
Intervention: No Intravenous Immunoglobulin (IVIG) treatment
Description: Questionnaires every two months for patients with a diagnosis of autoimmune dismotility that are not receiving Intravenous Immunoglobulin (IVIG) treatment.
Study: NCT06488144

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health coach
Description: Health Coaching

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health coach
Description: Health Coaching
Study: NCT05947136

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpretation of the results from the detection visit
Description: - An interpretation of the results of the detection tests concerning~* the 7 complications of interest assessed at T1, T2, T3 and T4 ;~* the 13 secondary complications assessed at T1, T3 and T4. This interpretation will be based on decision trees (1 tree/complication) to guide investigators in their decision-making and to standardise orientations;

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Explaining detection results and referrals to the patient
Description: Explanation of results and directions to the patient using plain language;The aims of this call are as follows:~* Clearly explain the results of the detection visit and the action to be taken for each referral;~* Evaluate the help to be given to the patient. This help will consist of making bookings with a healthcare professional in the PASCA network;~* Reassure patients about their results, but also make them aware of the importance of taking action to improve or prevent the onset of complications.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early medical care through the network
Description: Early, proactive medical care through a network of dedicated healthcare professionals.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Transmission of results from each detection visit to the referring onco-haematologists - Control Group
Description: For both the 7 complications of interest (primary objective) and the 13 secondary complications (secondary objective): all the data from each detection visit will be sent to the referring onco-haematologists, so that they can initiate their own management.
Study: NCT04968899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neofordex®
Description: Oral dexamethasone (Neofordex®) 40 mg (Day1 to Day 4), ± an additional 4-days cycle of dexamethasone between days 10 and 21.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous immunoglobulins
Description: IVIg (1g/kg D1-D2) plus oral prednisone (1 mg/kg/day x 21 days (3 weeks))
Study: NCT06488144

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remote Incentive Program
Description: Behavioral incentive program including gamification, social incentivization, and monitoring.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remote Incentive Program
Description: Behavioral incentive program including gamification, social incentivization, and monitoring.
Study: NCT06237296

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV/hMPV mRNA LNP 1
Description: Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular Injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV/hMPV mRNA LNP 1
Description: Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular Injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV/hMPV mRNA LNP 1
Description: Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular Injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV/hMPV mRNA LNP 1
Description: Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular Injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV/hMPV mRNA LNP 2
Description: Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular Injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV mRNA LNP 1
Description: Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular Injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hMPV mRNA LNP 1
Description: Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular Injection
Study: NCT04959838

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Impact of prolonged work
Description: Evaluate the impact of prolonged work (up to 60 consecutive hours) on the surgical capacities evaluated on a simulator, as well as on stress markers (questionnaires, saliva assays, skin conductance, quality of sleep) compared to a standard day.
Study: NCT05403242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC48-ADC
Description: 2.0 mg/kg, IV, d1, every 2 weeks; or 2.5 mg/kg, IV, d1, every 2 weeks
Study: NCT05736861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin
Description: Each participant will receive a sufficient quantity of 7-mg tablets to be taken as directed based on their weight. The tablets are white, round, biconvex tablets with 123 over the scoring on one side. All packaging will be labeled to indicate that the product is for investigational use.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each study arm will contain a placebo comparator. Placebo will look similar to study drug and will be administered via the same route of administration and dose. However, placebo will be an inactive substance, containing no study drug.
Study: NCT05469295

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CGM MB-1701 device treatment
Description: This is a pre-approved motorized traction device.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: CGM MB-1701 Sham device treatment
Description: It is manufactured in the same way as the test device and the operation pattern. However, the actual effect of the massage is minimized.
Study: NCT04981886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Netarsudil Ophthalmic
Description: Subjects will be randomly assigned to this group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Netarsudil Ophthalmic
Description: Subjects will be randomly assigned to this group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimatoprost Ophthalmic
Description: Subjects will be randomly assigned to this group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimatoprost Ophthalmic
Description: Subjects will be randomly assigned to this group
Study: NCT05986136

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesalamine
Description: Mesalamine, also known as 5-aminosalicylic acid (5-ASA), is a medication used to treat ulcerative colitis. It is usually used to induce or maintain remission of mildly to moderately active ulcerative colitis

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesalamine
Description: Mesalamine, also known as 5-aminosalicylic acid (5-ASA), is a medication used to treat ulcerative colitis. It is usually used to induce or maintain remission of mildly to moderately active ulcerative colitis

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin 10mg Tab
Description: Dapagliflozin has emerged as a selective SGLT2 inhibitor for the management of type-2 diabetes mellitus with minimal risk of hypoglycemia and it exerts diuretic-like actions and lowering of blood pressure, thereby, reducing the risk of hospitalization in type-2 diabetic patients with co-existing heart failure
Study: NCT05565560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: Oral tablets
Study: NCT04912232

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Detection of Occult Hemorrhage in Trauma Patients
Description: Non-invasive monitoring of trauma patients
Study: NCT06498882

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Press Needle Acupoint Stimulation Combined with Breast Massage
Description: Press needle acupoint stimulation and breast massage were administered. Key press needle acupoints were identified for selection: Dan zhong (RN17), bilateral Ru gen (ST18), bilateral Shao ze (SI1), bilateral Zu san li (ST36) and bilateral San yin jiao (SP6). The areas were sterilized with 75% alcohol before installing 0.22\*1.55mm press needles. Within 4-6 hours post-surgery, mothers received acupoint stimulation through needle pressing. This procedure was administered by nurses who had undergone six-month standardized training in traditional Chinese medicine techniques. Instructions were then given to mothers and their family members to stimulate the acupoints pulsatively every 3-4 hours for 20-30 minutes per session, removing the press needles after 24 hours. Additionally, a specialized nurse massaged the back, both breast areas, and armpits for 10-15 minutes, three times daily over three days, using a circular and oscillating breast massage device.

Intervention type: OTHER
Group type: OTHER
Intervention: routine care
Description: Very early skin-to-skin contact was initiated by researchers within 30 to 40 minutes after birth, with newborns, optionally wearing caps, being placed on the mothers' chests. Mothers were encouraged to breastfeed 8 to 10 times per day to ensure steady milk production. It was ensured by researchers that mothers completely emptied one breast before switching to the other to maintain cleanliness. Additionally, mothers were guided by researchers on maintaining a well-balanced diet, achieving emotional stability, and securing adequate sleep to facilitate effective breastfeeding.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: routine care
Description: Very early skin-to-skin contact was initiated by researchers within 30 to 40 minutes after birth, with newborns, optionally wearing caps, being placed on the mothers' chests. Mothers were encouraged to breastfeed 8 to 10 times per day to ensure steady milk production. It was ensured by researchers that mothers completely emptied one breast before switching to the other to maintain cleanliness. Additionally, mothers were guided by researchers on maintaining a well-balanced diet, achieving emotional stability, and securing adequate sleep to facilitate effective breastfeeding.
Study: NCT05113784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meplazumab for Injection
Description: humanized antibody target CD147

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile normal saline (0.9%)
Description: Sterile normal saline (0.9%)
Study: NCT06058104

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Charades based mobile digital therapeutic
Description: The mobile app is a charades style game and app that engages parent and child in fluid social interaction where the parent must guess what the child is acting out based on the prompt shown on the phone screen. Participants will use their own personal phone to download the study app. Parents are asked to play with their child 15 minutes 3-4 times per week for 8 weeks.
Study: NCT05370872

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Remote functional testing protocol
Description: Clients in the remote functional testing protocol group will be asked to describe their functional capacity limits using a clinician guided motivational interviewing approach and will also be asked to complete a mobility screening protocol to provide the clinician with the opportunity to observe the clients natural movements.
Study: NCT05289479

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pre-heating of resin composite before application
Description: the effect of preheating of resin composite before application in class II cavities

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pre-heating of resin composite before application
Description: the effect of preheating of resin composite before application in class II cavities

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: no pre-heating of resin composite before application
Description: The control group
Study: NCT06210230

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MLCT supplementation
Description: MLCT 25g/d for 6 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Olive oil
Description: Matching placebo (olive oil) 25g/d for 6 months
Study: NCT05076617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Staccato alprazolam
Description: * Pharmaceutical form: Inhalation powder~* Route of administration: Inhalation~Participants will receive Staccato alprazolam during the Treatment Period.
Study: NCT03991481

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cryopreserved platelets
Description: Platelets that have undergone a process to freeze, store and reconstitute platelets, extending their expiry to 2 years

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Liquid-stored platelets
Description: Liquid-stored platelets as per standard practice
Study: NCT04569942

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vasopressor
Description: Cease IV fluid resuscitation. If persisting hypotension and/or hypoperfusion commence a vasopressor infusion (e.g. noradrenaline) and titrate according to local practice to achieve target MAP. The target MAP will be determined by the treating clinician. Reassess at least hourly for up to 6 hours post-randomisation, then as clinically required in conjunction with the protocol. Boluses of 250ml of IV fluids are permitted if deemed indicated by the treating clinician.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fluids
Description: An fluid bolus of up to 1000ml will be administered over a maximum of 1 hour, if required, for persisting hypotension and/or hypoperfusion. Reassess at least hourly to 6 hours post-randomisation, then as clinically required in conjunction with the protocol. Further IV fluid boluses of 500ml are recommended as clinically indicated to achieve the target MAP. The target MAP will be determined by the treating clinician. Haemodynamic resuscitation will be guided by usual clinical assessment including vital signs, mentation, perfusion, and urine output until the treating clinician determines fluid resuscitation is no longer clinically required. A minimum of 2-3 L (30 ml/kg), including pre-randomisation fluids, is recommended within 3 hours of ED arrival consistent with the SSC guidelines, unless clinically contraindicated. Vasopressors may be commenced if blood pressure remains below target despite optimal fluid resuscitation as determined by the treating clinician.
Study: NCT05707403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1015550
Description: Treatment T

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1015550 mixed with [C-14]-BI 1015550
Description: Treatment R
Study: NCT06167031

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: chatbot facilitate teaching
Description: The experimental group will use chatbot to facilitate teaching.
Study: NCT05403242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: 40-60 mg, bid po, d1-10, every 2 weeks
Study: NCT06167031

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: lecture-based teaching
Description: The control group only receives lecture-based teaching.
Study: NCT04779684

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Advance care planning by proxy for health care proxies of people without medical decision making capacity
Description: Two discussions between a trained health professional and a health care proxy of an RACF resident who no longer has decision making capacity. First discussion focuses on life story, values, previous experiences with medical treatments, illness and death. Second discussion also includes treating physician and focuses on establishing general goals of care and medical orders in case of emergency.
Study: NCT05420246

Intervention type: DRUG
Intervention: Ainuovirine
Description: The regimen including Ainuovirine will be given to HIV-1 infected/AIDS patients.
Study: NCT05305300

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PIKA COVID-19 Vaccine (CHO cell, S-protein), Arm A
Description: receive two doses of PIKA COVID-19 vaccine (5 μg S protein/1mg PIKA, 10μg S protein/1mg PIKA and 20μg S protein/1mg PIKA) via IM administration on Days 0 and 7.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PIKA COVID-19 Vaccine (CHO cell, S-protein), Arm B
Description: receive one dose of PIKA COVID-19 vaccine (5 μg S protein/1mg PIKA, 10μg S protein/1mg PIKA and 20μg S protein/1mg PIKA) via IM administration on Days 0.
Study: NCT06261645

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Physiotherapist selected active exercises
Description: Exercises to restore total rotator cuff function selected and progressed according to patients performance. Performance is assessed by the physiotherapist regarding available range of motion, comfort during as well as pain-free performance.~Education on shoulder muscles functional anatomy and on effect of pain on muscle performance

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Delayed Physiotherapist selected active exercises
Description: Exercises to restore total rotator cuff function selected and progressed according to patients performance. Performance is assessed by the physiotherapist regarding available range of motion, comfort during as well as pain-free performance.~Education on shoulder muscles functional anatomy and on effect of pain on muscle performance
Study: NCT05385419

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Bronchoscopic and thoracoscopic frozen section biopsies
Description: Flexible bronchoscopy for patients with lung endobronchial lesion, the bronchoscopic biopsy will be sent for frozen section and permenant paraffin section Medical thoracoscopy for patients with undiagnosed pleural effusion, the thoracoscopic biopsy will be sent for both frozen section and permenant paraffin section
Study: NCT06251583

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: duramesh suture
Description: Duramesh-suture will be used for trocar closure in the experimental group

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: duramesh suture
Description: Duramesh-suture will be used for trocar closure in the experimental group
Study: NCT05855564

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mindfulness matters
Description: Classroom program will be provided to primary one students in eight primary schools and they will receive an 8 session mindfulness matters program, developed by Eline Snel, delivered by their teachers. Each session lasts for 30 minutes. The program includes mindfulness exercises, psychoeducation, discussion and sharing activities. For students with special needs, same programs will be delivered by teachers or social workers in small groups and each groups has 4 to 7 students. Program content is consistent with the classroom program.
Study: NCT06177145

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HASCV-R program
Description: Healthy nutrition, Active life, Ways to cope with Stress, Cancer and cancer screening, Vaccination - Reproductive health Training programme
Study: NCT05292378

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2500 ppm Carbon Dioxide
Description: 2.5 hour exposure to 2500 ppm carbon dioxide

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: 2500 ppm Carbon Dioxide
Description: 2.5 hour exposure to 2500 ppm carbon dioxide
Study: NCT05483517

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High energy density pulse electromagnetic field
Description: The treatment coil is placed over the shoulder region at the maximum pain point for 9 minutes. A normal energy of high-PEMF with a rate of 2 pulse per second is applied to the patient.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham High energy density pulse electromagnetic field
Description: The sham treatment coil is placed over the shoulder region at the maximum pain point for 9 minutes. The setting is the same as the experimental group(normal energy, a rate of 2 pulse per second) with the difference that the energy output doesn't export to the patient.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physiotherapy
Description: Physiotherapy includes shoulder range of motion (ROM), stretching and muscle strengthening exercises. Under the physiotherapist's guidance, the patient receives the training session about 30 minutes every time.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: physiotherapy
Description: Physiotherapy includes shoulder range of motion (ROM), stretching and muscle strengthening exercises. Under the physiotherapist's guidance, the patient receives the training session about 30 minutes every time.